Vitamin D Deficiency Clinical Trial
Official title:
A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
1. Study content: This is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin D insufficiency or deficiency in patients with CKD5d; to investigate whether vitamin D supplementation delays the increase in PTH levels in this group of patients; and to investigate the effects on changes in CKD-MBD-related markers, cardiovascular complications, cognitive function in this group of patients. 2. Study procedure: Based on the inclusion and exclusion of the patients, the study was conducted in accordance with the following criteria 2. Study procedure: Eligible subjects were screened according to inclusion and exclusion criteria and randomly divided into three groups: high-dose vitamin D group, low-dose vitamin D group and control group. Baseline data were collected before the intervention and each group was given different doses of regular vitamin D2 softgels or placebo and followed up. 25(OH)D, PTH, blood Ca, and blood P levels were measured every month; bone metabolism markers, FGF23, and blood counts, liver function, kidney function, lipids, and blood glucose were measured every 3 months; the prevalence of vascular calcification, the incidence of cardiovascular events, and changes in cognitive function scale scores were assessed 6 months after the intervention.
Status | Recruiting |
Enrollment | 372 |
Est. completion date | October 30, 2023 |
Est. primary completion date | August 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. Age = 18 years. 2. Patients with chronic kidney disease stage 5d who have been on haemodialysis for 3 months or more 3. 5 ng/mL < 25(OH)D < 30 ng/mL (liquid phase tandem mass spectrometry). 4. 130 pg/ml < PTH < 600 pg/ml (electrochemiluminescence method). 5. serum phosphorus < 1.78 mmol/L. 6. Good compliance with the treatment requirements formulated for the study. 7. informed consent from the subject. Exclusion Criteria: 1. Patients who are prepped for or have undergone renal transplantation or parathyroidectomy. 2. taking vitamin D, active vitamin D or analogues and other drugs that may affect 25(OH)D levels within 3 months prior to enrolment 3. Treatment affecting PTH results (e.g. cenacaser, etc.) within 3 months prior to enrolment 4. Serum calcium > 2.55 mmol/L 5. Patients who are pregnant or likely to become pregnant, breastfeeding or planning to become pregnant during the study period 6. known prior or concomitant serious illness or medical condition such as malignancy, human immunodeficiency virus, severe gastrointestinal or liver disease, intestinal malabsorptive disease, hepatitis or cardiovascular events that may worsen or shorten life expectancy and/or interfere with participation in the study 7. History of neurological/psychiatric disease, including psychosis or dementia, or any other reason that is unlikely to result in adherence to treatment or follow-up plans. 8. Known or suspected allergy to any component of the study drug. 9. Ongoing participation in other clinical studies. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Xi 'an Jiaotong University | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital Xi'an Jiaotong University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differences in changes in PTH levels from baseline to 6 months of intervention | baseline,at 6 months intervention | ||
Secondary | Differences in changes in PTH levels from baseline to intervention at 1months?2months?3months?4months?5months | baseline,at 1,2,3,4,5 months intervention | ||
Secondary | Proportion of 25(OH)D >30ng/ml at 3 months of intervention | at 3 months intervention | ||
Secondary | Trends in changes in 25(OH)D levels from baseline to intervention at 1months?2months?3months?4months?5months?6months | baseline,at 1,2,3,4,5,6 months intervention | ||
Secondary | Incidence of cardiovascular events after 6 months of intervention | baseline,at 6 months intervention | ||
Secondary | Change in prevalence of vascular calcification at 6 months of intervention | We used cardiac ultrasound and lateral abdominal views to look for vascular calcification | baseline,at 6 months intervention | |
Secondary | Change in Montreal Cognitive Assessment Scale scores at 6 months of intervention | A total score of 30 on this scale, with a score of =26 indicating normal; a score of <26 indicates the presence of cognitive impairment: 18-26 for mild cognitive impairment, 10-17 for moderate cognitive impairment and <10 for severe cognitive impairment | baseline,at 6 months intervention | |
Secondary | Trends in blood calcium levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention | baseline,at 1,2,3,4,5,6 months intervention | ||
Secondary | Trends in blood phosphorus levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention | baseline,at 1,2,3,4,5,6 months intervention | ||
Secondary | Trends in FGF23 levels at 3 and 6 months of intervention | baseline,at 3,6 months intervention | ||
Secondary | Trends in Osteocalcin(OC) levels at 3 and 6 months of intervention | baseline,at 3,6 months intervention | ||
Secondary | Trends in Precollagen type I amino-terminal peptide(PINP) levels at 3 and 6 months of intervention | baseline,at 3,6 months intervention | ||
Secondary | Trends in ß specific collagen degradation products(ß-CTX) levels at 3 and 6 months of intervention | baseline,at 3,6 months intervention | ||
Secondary | Trends in ALP levels at 3 and 6 months of intervention | baseline,at 3,6 months intervention | ||
Secondary | Incidence of fractures at 6 months of intervention | Ask if the patient had a fracture during the intervention, the site of the fracture and the type of fracture | baseline,at 6 months intervention | |
Secondary | Incidence of falls at 6 months of intervention | Ask if the patient has fallen during the intervention, the number of falls and the reasons for them | baseline,at 6 months intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05459298 -
ViDES Trial (Vitamin D Extra Supplementation)
|
N/A | |
Completed |
NCT04476511 -
The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules
|
Phase 3 | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03920150 -
Vitamin D 24'000 IU for Oral Intermittent Supplementation
|
Phase 3 | |
Completed |
NCT03264625 -
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
|
Phase 2 | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT05506696 -
Vitamin D Supplementation Study
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Completed |
NCT03234218 -
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
|
||
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT02906319 -
Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|
N/A | |
Completed |
NCT02714361 -
A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women
|
N/A | |
Completed |
NCT02118129 -
Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.
|
N/A | |
Not yet recruiting |
NCT01419821 -
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
|
N/A | |
Completed |
NCT02275650 -
The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter
|
N/A | |
Completed |
NCT02187146 -
The Effects of Serum Vitamin D and IVF Outcome
|
N/A | |
Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 | |
Completed |
NCT01688102 -
The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile
|
N/A |